Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Gilead Sciences GILD NASDAQ:GILD

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc (NASDAQ:ITMN) stock performance was -0.88% in last session and finished the day at $39.63. Traded volume was 2.82million shares in the last session and the average volume of the stock remained 3.78million shares. The beta of the stock remained 4.80. InterMune Inc (NASDAQ:ITMN) insider ownership is 0.30%.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), after the big top and breakaway gap a few weeks ago, it coiled very tightly and quietly, and suddenly picked up. It’s been up four days in a row, and on Tuesday, it took out the May 1st 7.65 line, up 48 cents, or 6.38%, on 2.6 million shares, closing at 8.00. It’s a beautiful chart. Looking for something around 11ish. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rose 6.38 percent to $8.00 Tuesday on volume of 2.69million shares. The intra-day range of the stock was $7.57 to $8.06. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has a market capitalization of $827.24million.

Jefferies Group assumed coverage on shares of China Biologic Products Inc (NASDAQ:CBPO) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $52.00 price objective on the stock. “CBPO is a leading fully integrated plasma-based supplier in China. In an industry with high entry barriers and limited competition, CBPO is expected to outgrow the market in the next 5 years, given its solid control of plasma supply, comprehensive product portfolio, robust pipeline, and potential M&A. Initiate coverage with BUY and US$52 PT.,” Jefferies Group’s analyst wrote. China Biologic Products Inc (NASDAQ:CBPO)’s stock on May 27, 2014 reported a increase of 3.66% to the closing price of $45.27. Its fifty two weeks range is $19.10 -$45.60. The total market capitalization recorded $1.06billion. The overall volume in the last trading session was 40,092.00million shares. In its share capital, CBPO has 23.44million outstanding shares.

VIVUS, Inc. (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. On Tuesday, shares of VIVUS, Inc. (NASDAQ:VVUS) advanced 0.65% to close the day at $4.67. Company return on investment (ROI) is -42.20% and its monthly performance is recorded as -10.02%. VIVUS, Inc. (NASDAQ:VVUS) quarterly revenue growth is -20.31%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced  that the company is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Grand Hyatt in New York, New York. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 1.94% in last session and finished the day at $6.31. Traded volume was 3.32million shares in the last session and the average volume of the stock remained 5.50million shares. The beta of the stock remained -0.32. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone